scholarly journals Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn

2009 ◽  
Vol 31 (2) ◽  
pp. 223-236 ◽  
Author(s):  
Kristi Baker ◽  
Shuo-Wang Qiao ◽  
Timothy Kuo ◽  
Kanna Kobayashi ◽  
Masaru Yoshida ◽  
...  
Author(s):  
Victoria P. Werth ◽  
Donna A. Culton ◽  
Josef S.S. Concha ◽  
James S. Graydon ◽  
Laurence J. Blumberg ◽  
...  

2000 ◽  
Vol 27 (4) ◽  
pp. 231-240 ◽  
Author(s):  
J. E. Mikulska ◽  
L. Pablo ◽  
J. Canel ◽  
N. E. Simister

Placenta ◽  
2009 ◽  
Vol 30 (6) ◽  
pp. 507-515 ◽  
Author(s):  
R. Szlauer ◽  
I. Ellinger ◽  
S. Haider ◽  
L. Saleh ◽  
B.L. Busch ◽  
...  

Blood ◽  
2011 ◽  
Vol 118 (24) ◽  
pp. 6403-6406 ◽  
Author(s):  
Andrew R. Crow ◽  
Sara J. Suppa ◽  
Xi Chen ◽  
Patrick J. Mott ◽  
Alan H. Lazarus

Abstract To definitively determine whether the neonatal Fc receptor (FcRn) is required for the acute amelioration of immune thrombocytopenia (ITP) by IVIg, we used FcRn-deficient mice in a murine ITP model. Mice injected with antiplatelet antibody in the presence or absence of IVIg displayed no difference in platelet-associated IgG between FcRn deficient versus C57BL/6 mice. FcRn-deficient mice treated with high-dose (2 g/kg) IVIg or a low–dose (2 mg/kg) of an IVIg-mimetic CD44 antibody were, however, protected from thrombocytopenia to an equivalent extent as wild-type mice. To verify and substantiate the results found with FcRn-deficient mice, we used β2-microglobulin–deficient mice (which do not express functional FcRn) and found that IVIg or CD44 antibody also protected them from thrombocytopenia. These data suggest that for both high-dose IVIg as well as low-dose CD44 antibody treatment in an acute ITP model, FcRn expression is neither necessary nor required.


2000 ◽  
Vol 113 (7) ◽  
pp. 1277-1285 ◽  
Author(s):  
K.M. McCarthy ◽  
Y. Yoong ◽  
N.E. Simister

The neonatal Fc receptor, FcRn, transports immunoglobulin G (IgG) across cellular barriers between mother and offspring. FcRn also protects circulating IgG from catabolism, probably during transport across the capillary endothelium. Only one cell culture model of transcytosis has been used extensively, the transport of IgA from the basolateral to the apical surface of Madin-Darby canine kidney cells by the polymeric immunoglobulin receptor (pIgR). We report that rat inner medullary collecting duct (IMCD) cells transfected with DNA encoding the (alpha) subunit of rat FcRn specifically and saturably transport Fc when grown as polarized monolayers. Using this system, we have found that transcytosis by FcRn, like transcytosis by the pIgR, depends upon an intact microtubule system. FcRn differs most strikingly from the pIgR in its ability to transport its ligand in both the apical to basolateral and basolateral to apical directions. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibited basolateral to apical transport by FcRn more than apical to basolateral transport, suggesting that there are differences in the mechanisms of transport in the two directions. Lastly, we found that transcytosis by FcRn depends upon vesicular acidification. We anticipate that the IMCD cell culture model will allow further elucidation of the mechanism of IgG transport by FcRn.


2017 ◽  
Vol 292 (42) ◽  
pp. 17449-17460 ◽  
Author(s):  
Jon A. Kenniston ◽  
Brandy M. Taylor ◽  
Gregory P. Conley ◽  
Janja Cosic ◽  
Kris J. Kopacz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document